Annual Report

2026

VECTUS BIOSYSTEMS LIMITED
AND CONTROLLED ENTITY
ACN 117 526 137

GENERAL INFORMATION

The financial report covers Vectus Biosystems Limited as a consolidated entity consisting of Vectus Biosystems Limited and the entity it controls. The financial report is presented in Australian dollars, which is Vectus Biosystems Limited's functional and presentation currency.

The financial report consists of financial statements, notes to the financial statements and the Directors' declaration.

Vectus Biosystems Limited is a listed public company limited by shares, incorporated and domiciled in Australia.

REGISTERED OFFICE

Unit 5, Ground Floor
26-34 Dunning Avenue
Rosebery NSW 2018 Australia

The Financial Report was authorised for issue in accordance with a resolution by the Board of Directors on 26 August 2026.

Contents





Chairman’s Report

The 2025-26 financial year saw Vectus Biosystems Limited (Vectus or the Company) enter a new era, with the Company taking several meaningful steps towards advancing and realising value from its portfolio of antifibrotic drug candidates.

Vectus announced an important, major change in leadership, with Dr Tara Speranza appointed as the Company’s Chief Executive Officer and Chief Technology Officer after having worked closely with Vectus as a consultant since August 2025. Tara brings a combination of scientific, drug development, commercial and capital markets experience that is particularly relevant to the Company’s next stage. The Board believes her appointment gives Vectus stronger internal capability to assess development opportunities, engage with potential partners, and progress the Company’s assets in a disciplined and commercially-focused manner. Since taking on her new role, Tara has begun articulating a clearer development strategy for the portfolio, with an initial emphasis on the further advancement of VB0004. This reflects a more disciplined approach to the portfolio as a whole, directing Vectus’ resources towards the opportunities most capable of generating clinical and commercial value.

The Company has remained focused on the commercialisation of its intellectual property and engagement with potential pharmaceutical partners. Vectus has strengthened its capacity to progress the clinical development of VB0004, while achieving an important commercial outcome for another asset in its portfolio.

The completion of the transaction with XORTX Therapeutics Inc. (XORTX) for the VB4-P5 renal fibrosis compound was a particularly-significant milestone. The transaction provides the Company with an equity interest in XORTX and ongoing exposure to the future development of VB4-P5, without requiring Vectus to fund that development itself. For the Board, the importance of this transaction extends beyond VB4-P5. It demonstrates that the work undertaken over many years to develop, validate and protect the Company’s compounds can provide a basis for transactions with external biotechnology and pharmaceutical groups. This remains an important component of Vectus’ strategy for its broader portfolio.

VB0004 remains central to the Company’s plans. During the year, Vectus continued its engagement with prospective partners, and worked to strengthen the clinical and regulatory pathway for this compound. The Company’s objective is to ensure that VB0004 is positioned to progress through the most appropriate combination of internal development, partnering and external funding. This strategy received further support in May 2026 with the completion of a $791,000 placement. The funds provide additional capacity to progress clinical work associated with VB0004 and Vectus’ other emerging drug programmes.

Subsequent to the end of the 2025-26 financial year, the Company appointed Cardinal Health Regulatory Services (CHRS) as its United States of America (USA) regulatory agent. CHRS will assist Vectus with its activities with the Food and Drug Administration in the USA, including preparations for an Orphan Drug Designation request, pre-Investigational New Drug (IND) interactions and an IND application for VB0004 in idiopathic pulmonary fibrosis. This work gives the Company a more defined regulatory pathway as it considers the next stage of its clinical development.

Throughout the year, Vectus also continued to engage directly with selected potential pharmaceutical partners and with the support of its business development consultant, C14 Consulting Group, LLC, on VB0004 and the Company's broader portfolio. Vectus remains conscious that biotechnology development requires both capital and specialist expertise, and the Board continues to consider partnering and licensing opportunities as an important means of progressing the Company's assets efficiently.

The progress made during the year leaves Vectus in a much stronger position than it was 12 months ago. The Company has completed a transaction that demonstrates the commercial potential of the portfolio, strengthened Vectus' leadership, secured additional funding and begun establishing the regulatory pathway for the next stage of VB0004's development. There remains significant work ahead, and the Board is focused on execution and disciplined use of capital as the Company moves into the next stage.

I would like to thank Tara, our advisors and our consultants for their commitment during the year, as well as my fellow Directors for their ongoing contribution to Vectus. Most importantly, I thank our shareholders for their continued support.
We look forward to building on the progress made during the 2025-26 financial year as the Company advances VB0004 and continues to pursue opportunities to realise value from its broader drug portfolio.

Dr Ronald Shnier
Non-Executive Chairman

28 August 2026



Review of Operations

Vectus Biosystems Limited (Vectus or the Company) reports on its operations and results for the year ended 30 June 2026.

APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND CHIEF TECHNOLOGY OFFICER

Vectus entered a new era in its development with the appointment of Dr Tara Speranza as its Chief Executive Officer and Chief Technology Officer, effective 7 May 2026. Dr Speranza had provided consulting services to the Company since August 2025 and commenced the new role with an established understanding of Vectus' scientific platform, VB0004, and its broader portfolio of drug candidates. She brings more than two decades of experience spanning scientific research, translational drug development, biotechnology commercialisation, and strategic advisory and capital markets. Dr Speranza's prior work includes senior research positions at the University of Sydney and the University of Geneva, involvement in a commercial partnership with global pharmaceutical company Servier, and investment, advisory and capital markets roles supporting healthcare and biotechnology companies. Her appointment strengthens the Company's internal scientific, commercial and transaction capabilities as it advances VB0004, and continues its engagement with potential strategic, licensing and commercial partners.

VB0004 DEVELOPMENT

During the year, Vectus continued to progress the clinical and commercial foundations required to support the further development of VB0004. The Company continued to expand its data room with clinical, technical and intellectual property (IP) information prepared by Vectus and its specialist consultants. This material supports the Company's future development planning, and the assessment of VB0004 by potential pharmaceutical and biotechnology partners.

In May 2026 Vectus completed a placement of 7,910,000 new fully paid ordinary shares at $0.10 per share, raising $791,000. The proceeds are being applied towards accelerating further clinical trial work for VB0004, progressing other emerging lead compounds and providing working capital.

Subsequent to the end of the financial year, the Company appointed Cardinal Health Regulatory Services (CHRS) as its regulatory agent in the United States of America. CHRS will act as the primary point of contact for the Food and Drug Administration-facing regulatory activities relating to VB0004 and, potentially, other pipeline assets. CHRS will assist with regulatory communications and submissions, including an Orphan Drug Designation (ODD) request, pre-Investigational New Drug (IND) communications and an IND application for VB0004 in Idiopathic Pulmonary Fibrosis (IPF).

VB4-P5 RENAL COMPOUND TRANSACTION

During the year, Vectus completed the sale of its VB4-P5 renal small-molecule compound to XORTX Therapeutics Inc. (XORTX), the Canadian biotechnology company listed on the Nasdaq stock exchange.

The transaction closed on 14 April 2026 following satisfaction of the relevant closing conditions. As consideration, XORTX issued the Company with 154,544 common shares, representing approximately 9.9% of XORTX's issued share capital at completion, together with 692,150 pre-funded warrants. The warrants may be exercised into XORTX shares without any additional material payment by Vectus. Portions of the securities received were subject to voluntary lock-up periods ranging from 45 to 180 days.

Under the transaction, XORTX acquired the patents, IP and data specifically relating to VB4-P5, and its potential application in renal fibrosis and kidney disease. The Company retained a licence to the relevant patents and IP for potential applications outside those fields. Through its equity interest in XORTX, Vectus retains exposure to the future development and commercialisation of VB4-P5 and XORTX's broader development portfolio without being required to provide further funding for those programmes. The transaction is consistent with the Company's strategy of progressing and validating drug candidates before seeking appropriately-positioned partners to undertake further development and commercialisation.

PHARMACEUTICAL COMPANY ENGAGEMENT

Throughout the year, Vectus continued its commercialisation and partnering programmes, approaching selected pharmaceutical companies directly as well as through its business development consultant, C14 Consulting Group, LLC. The programme covered VB0004, VB4-A32, VB4-A79 and compounds from the Company's broader drug library. Discussions continued with potential licencees and strategic partners, with selected pharmaceutical industry participants provided with access to Vectus' data room.

The Company remains focused on identifying appropriate commercial and development pathways for individual assets, including licensing arrangements, collaborative development programmes and other strategic transactions.

FINANCIAL UPDATES

During the year, Vectus continued to manage its expenditure while focusing its resources on commercialisation, IP maintenance, and the further development of VB0004 and its emerging lead compounds.

The Company received a $422,000 research and development refund from the Australian Taxation Office in September 2025. In May 2026 Vectus raised $791,000 through the issue of 7,910,000 new fully paid ordinary shares at $0.10 per share. At 30 June 2026 the Company had cash of $718,000.

Vectus recorded a profit after tax of $1,558,651 for the year ended 30 June 2026 (with a re-stated loss of $1,862,377 for the year ended 30 June 2025). Operating expenses were $1,412,474 in the 2025-26 financial year compared to $2,340,559 in the 2024-25 financial year.

SUMMARY

Under the leadership of Dr Speranza, the Company is now focused on taking VB0004 into a Phase Ib clinical trial, targeting patients with IPF, which is a rare disease with significant unmet need, creating the opportunity for an ODD.

Vectus maintains its broad IP and platform, with a drug library of more than 1,000 small compound drug candidates creating a range of partnering and licensing opportunities.

The Company continues its capital-efficient model, remaining focused on high-value opportunities with potential to significantly increase shareholder value.



Directors' Report

For the year ended 30 June 2026

The Directors of Vectus Biosystems Limited present their Report together with the financial statements of the consolidated entity, being Vectus Biosystems Limited (the Company) and its controlled entity (the Group) for the year ended 30 June 2026.

DIRECTORS' DETAILS

The names of the Directors in office at any time during, or since, the end of the year are:

Ronald Shnier

Maurie Stang

Linda Walters

REVIEW OF OPERATIONS AND FINANCIAL RESULTS

The consolidated profit after tax of the Group for the 2026 financial year amounted to $1,558,651 (2025: re-stated loss $1,862,377).

For a comprehensive review of the Group's operational performance, refer to the attached Review of Operations.

A review of the Group's operations during the financial year and the results of those operations are as follows:

- the Group's operations during the financial year performed as expected in the opinion of the Directors; and
- no significant change in the nature of these activities occurred during the financial year.

PRINCIPAL ACTIVITIES

During the financial year the principal continuing activities of the Group consisted of:

- Medical Research and Development

MATTERS SUBSEQUENT TO THE END OF THE FINANCIAL YEAR

There have been no matters or circumstances, which have arisen since 30 June 2026 that have significantly affected or may significantly affect:

a. the operations, in financial years subsequent to 30 June 2026, of the Group; or

b. the results of those operations; or

c. the state of affairs, in the financial years subsequent to 30 June 2026, of the Group.

LIKELY DEVELOPMENTS AND EXPECTED RESULTS OF OPERATIONS

Likely developments in the operations of the Group and the expected results of those operations in future financial years have not been included in this Report as the inclusion of such information is likely to result in unreasonable prejudice to the Group.

SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS

On 17 October 2025, the Company announced that it had signed a binding term sheet with XORTX Therapeutics Inc. (XORTX) for the sale of the Company's VB4-P5 Renal Small Molecule Compound targeting renal fibrosis. The consideration of $2.6 million is to be satisfied by XORTX issuing the Company with both shares and pre-funded warrants (which can be exercised to receive shares for no additional payment by Vectus). The transaction closed on 14 April 2026 and the Company received a direct shareholding in XORTX in the form of 154,544 common shares and 692,150 pre-funded warrants.

This transaction fits with Vectus' strategy of developing, and carrying out early validation work on, its drug candidates to the point where they become commercially attractive to pharmaceutical partners. XORTX is a Canadian biotechnology company listed on the Nasdaq, which is focused on drug development.

On 22 May 2026 the Company announced the completion of a $0.8 million placement to accelerate its VB0004 clinical trial work and other drug programmes. This was supported by a number of institutional and sophisticated investors, through a placement of 7,910,000 new fully paid ordinary shares at $0.10 per share. For each Vectus share issued, the applicant shall receive a Vectus option exercisable at $0.20 and the options will be issued following approval at the Company's next shareholder meeting. The net proceeds of the placement will be used to accelerate the Phase Ib clinical trial for VB0004, which targets the prevention and reversal of fibrosis in the lungs, heart and kidneys. Proceeds will also be used to advance Vectus' other emerging lead compounds and for working capital.

There have been no other significant changes in the state of affairs of the consolidated entity during the year ended 30 June 2026.

DIVIDENDS

There were no dividends paid during the year.

There were no dividends or distributions recommended or declared for payment to members during the year that have not been paid or credited to the member throughout the year.

ENVIRONMENTAL REGULATION

The Group is not subject to any significant environmental regulation under Australian Commonwealth or state law.

INDEMNITY AND INSURANCE OF OFFICERS AND AUDITORS

The Company has indemnified the directors and executives of the Group for the costs incurred, in their capacity as a Director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Company paid a premium in respect of a contract to insure the Directors and executives of the Group against a liability to the extent permitted by the Corporations Act 2001. The contract of insurance prohibits disclosure of the nature of liability and the amount of the premium.

INDEMNITY AND INSURANCE OF AUDITOR

The Company has agreed to indemnify the auditor, UHY Haines Norton, to the extent permitted by law.

PROCEEDINGS ON BEHALF OF THE COMPANY

No person has applied for leave of the Court to bring proceedings on behalf of the Company or intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or any part of those proceedings.

The Company was not a party to any such proceedings during the year.

BOARD OF DIRECTORS, CEO & CTO, AND COMPANY SECRETARY

Vectus Biosystems Limited's (Vectus or the Company) Board has a broad range of experience in drug research and development, and early stage biotech companies, capital markets, financial and scientific expertise.

Dr Ronald Shnier
Non-Executive Chairman

Dr Ronald Shnier completed his radiology fellowship at Royal Prince Alfred Hospital (RPAH) before undertaking his neuroradiology fellowship at RPAH in 1989 and musculoskeletal fellowship at the University of California Los Angeles (UCLA) in 1991. He was a consultant specialist at RPAH between 1990 and 1993.

Dr Shnier started one of Australia's first Private MRI practices in 1991 before becoming General Manager of Mayne's Diagnostic Imaging in 2007 and was its National Director for many years. He has served on several international MRI advisory boards.

Dr Shnier has a strong involvement in clinical research, and has lectured both in Australia and overseas. He was formerly the Chief Medical Officer of I-MED Radiology Network and an executive director on the board, and is now a non-executive director. Dr Shnier is also currently a non-executive director on the Board of Lumitron Technologies.

Directorships held in other listed entities in the past three years:
None

Appointed to the Board:
2 September 2015

Mr Maurie Stang
Non-Executive Deputy Chairman

Mr Maurie Stang has more than four decades of experience building and managing companies in the healthcare and biotechnology industry in Australia and internationally. His strong business development and marketing skills have resulted in the successful commercialisation of intellectual property across global markets. Mr Stang has been the Executive Chairman of unlisted company Lumitron Technologies since 2016.

Directorships held in other listed entities in the past three years:
Non-Executive Chairman of Aeris Environmental Ltd (ASX:AEI) since 24 July 2002.

Appointed to the Board:
12 December 2005

Ms Linda Walters
Non-Executive Director

Ms Linda Walters (BEc Hon MAICD) has a strong operational, commercial and technical background across a number of life sciences, biotechnologies and health care companies. She has held senior leadership positions supporting both listed and unlisted Australian companies for over 25 years.

Ms Walters has made a significant contribution to Vectus since its inception and public listing, and has a detailed knowledge of the Company's technologies, intellectual property (IP) and commercialisation programme.

Her expertise spans the fields of human resources, finance, information technology and the commercialisation of IP. Ms Walters has served with Regional Health Care Group and Henry Schein in a number of senior leadership roles, and was instrumental in developing Vectus' operational and commercial capabilities.

Directorships held in other listed entities in the past three years:
None

Appointed to the Board:
20 December 2024

Dr Tara Speranza
Chief Executive Officer and Chief Technology Officer

Dr Tara Speranza brings over two decades of experience spanning scientific research, commercial strategy and capital markets within the healthcare and biotechnology sectors. She has over a decade of experience in academia, holding senior research positions at the University of Sydney and the University of Geneva, where her research focused on novel molecular targets and translational drug development.

During this time, Dr Speranza led a successful commercial partnership with global pharmaceutical company, Servier, resulting in the development and commercialisation of the anti-osteoporotic therapy, Protelos. Following her academic career, she has held roles across investment, strategic advisory and capital markets, supporting biotechnology and healthcare companies in valuation, capital raising, and strategic positioning.

Dr Speranza has been directly involved in assessing and progressing investments and partnerships across a range of early- and late-stage healthcare assets, including licensing and transaction processes.

Appointed as CEO and CTO:
7 May 2026

Mr Robert Waring
Company Secretary

Mr Robert Waring (BEc, CA, FCIS, FFin, FAICD) has over 50 years of experience in financial and corporate roles, including over 30 years in Company Secretarial roles for ASX-listed companies, and over 20 years as a Director of ASX-listed companies.

Mr Waring has significant company secretarial experience for both listed and unlisted companies, and is currently serving as Company Secretary for ASX-listed company Aeris Environmental Ltd (ASX:AEI).

He is a Director of Oakhill Hamilton Pty Ltd, which provides secretarial and corporate advisory services to a range of listed and unlisted companies.

Appointed as Company Secretary:
9 July 2015

MEETINGS OF DIRECTORS

The number of meetings of the Company's Board of Directors (the Board) and of each Board Committee held during the year ended 30 June 2026, and the number of meetings attended by each Director / Committee member, were:

	Board of Directors Meetings	Audit and Risk Management Committee Meetings	Remuneration and Nomination Committee Meetings	Corporate Governance Committee Meetings
NUMBER OF MEETINGS HELD	11	4	1	-
NUMBER OF MEETINGS ATTENDED				
Ronald Shnier	10	3	1	N/A
Maurie Stang	10	3	1	-
Linda Walters *	11	4	1	-

* On 22 July 2026 Linda Walters was elected Chair of the Corporate Governance Committee.

COMMITTEE MEMBERSHIP

As at the date of this report, the Company had an Audit and Risk Management Committee, a Corporate Governance Committee, a Remuneration and Nomination Committee, and a Disclosure Committee of the Board of Directors. Members acting on the Committees of the Board are:

Audit and Risk Management Committee

Linda Walters (Chair)
Maurie Stang
Ronald Shnier

Remuneration and Nomination Committee

Maurie Stang (Chair)
Ronald Shnier
Linda Walters

Corporate Governance Committee

Linda Walters (Chair)
Maurie Stang

Disclosure Committee

Made up of two Directors, which would normally be the Chairman (Ronald Shnier) and another Non-Executive Director.
This Committee approves ASX announcements when the full Board is not available.

SHARE REGISTRY

Computershare Investor Services Pty Limited
GPO Box 2975, Melbourne VIC 3001, Australia

Telephone Australia: 1300 850 505

Telephone International: +61 3 9415 4000

Website: http://www.computershare.com

Contact: www.investorcentre.com/contact

AUDITOR'S INDEPENDENCE DECLARATION

UHY Haines Norton continues in office in accordance with section 327 of the Corporations Act 2001.

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 18.

OFFICERS OF THE COMPANY WHO ARE FORMER AUDIT PARTNERS OF UHY HAINES NORTON

There are no officers of the Company who are former audit partners of UHY Haines Norton.

CORPORATE GOVERNANCE

Vectus Biosystems Limited's Corporate Governance Statement and ASX Appendix 4G are released to ASX on the same day the Annual Report is released.

The Company's Corporate Governance Statement, and Corporate Governance Compliance Manual, can both be found on the Company's website at:
http://www.vectusbiosystems.com.au/investor-centre/corporate-governance.

DIRECTORS' INTERESTS

	Ordinary Shares	Options or rights over ordinary shares
Ronald Shnier	345,791	-
Maurie Stang	4,889,452	316,000
Linda Walters	31,667	-

Remuneration Report (Audited)

KEY MANAGEMENT PERSONNEL (KMP)

The key management personnel of the Company comprise the Directors and the Chief Executive Officer, as follows:

Ronald Shnier

Maurie Stang

Linda Walters

Tara Speranza
Appointed as CEO and CTO on 7 May 2026

REMUNERATION POLICIES

Details of Vectus' remuneration policies and practices, together with details of Directors' and Executives' Remuneration, are as follows:

a/ Overview of remuneration structure:

The objective of the Company's executive reward framework is to ensure reward for performance is competitive and appropriate for the results delivered. Processes have been established to ensure that the levels of compensation and remuneration are sufficient and reasonable, and explicitly linked to the achievement of personal and corporate objectives. The short and long-term incentive plans are specifically aligned to shareholder interests.

Vectus' Remuneration and Nomination Committee advises the Board on remuneration policies and practices generally, and makes specific recommendations on remuneration packages and other terms of employment for staff, including Directors and Senior Managers of the Company.

The Committee has access to the advice of independent remuneration consultants but has not used their services during the year.

b/ Non-Executive Directors:

Payments were not made during the year to Non-Executive Directors for their services, and accordingly, their fees have been accrued and appear as Current liabilities. This is reviewed annually.

c/ Executives

The objective of Vectus' executive reward system is to ensure that remuneration for performance is competitive and appropriate for the results delivered.

Executive pay structures include a base salary and superannuation. In addition, executives and senior managers can participate in the Employee Incentives Plan.

EQUITY HOLDING TRANSACTIONS

The movement during the reporting period in the number of ordinary shares in Vectus Biosystems Limited held directly, indirectly, or beneficially by each specified Director and specified executive including their personally-related entities, are as follows:

2026	Number held 30 June 2025	Acquired during year	Sold during year	Number held 30 June 2026
Ronald Shnier	345,791	-	-	345,791
Maurie Stang	4,889,452	-	-	4,889,452
Linda Walters	31,667	-	-	31,667
Tara Speranza*	-	305,200	-	305,200
	5,266,910	**305,200**	**-**	**5,572,110**

2025	Number held 30 June 2024	Acquired during year	Sold during year	Number held 30 June 2025
Ronald Shnier	345,791	-	-	345,791
Maurie Stang	4,889,452	-	-	4,889,452
Linda Walters	-	31,667	-	31,667
Karen Duggan***	3,298,342	-	3,298,342	-
Susan Pond**	40,250	-	-	40,250
	8,573,835	**31,667**	**3,298,342**	**5,307,160**

*** Ceased to be a Director on 19 May 2024

** Ceased to be a Director on 27 November 2024

* Appointed to CEO and CTO on 7 May 2026

TRANSACTIONS WITH DIRECTORS AND DIRECTOR RELATED ENTITIES

A number of specified directors, or their personally-related entities, hold positions in other entities that result in them having control or significant influence over the financial or operating policies of those entities.

A number of these entities transacted with the Company in the reporting period. The terms and conditions of those transactions were no more favourable than those available, or which might reasonably be expected to be available, on similar transactions to unrelated entities on an arms length basis.

Details of these transactions and outstanding balances are shown below:

	2026 $	2025 $
Regional Corporate Services Pty Ltd		
Corporate and administration services	145,263	233,520
Current payables	373,229	240,734
Maurie Stang is a director and shareholder of Regional Corporate Services Pty Ltd.		
Loan from Maurie Stang, Non-Executive Deputy Chairman		
Loan borrowing	250,000	200,000
Loan repaid	-	-
Interest on loan capitalised	37,001	-
Outstanding balance	487,001	200,000
Balances outstanding to Directors		
Directors' fees payable to Maurie Stang	100,375	45,375
Directors' fees payable to Ronald Shnier	118,625	53,625
Directors' fees payable to Linda Walters	68,885	23,885

Details of **Directors' and Executive Officers'** remuneration for the year ended 30 June 2026

2026	Short-term benefits Salary & Directors' fees $	Post employment benefits $	Equity based benefits Shares $	Equity based benefits Options or Rights $	Total $	Performance related %
Non-Executive Directors'						
Ronald Shnier	58,036	6,964	-	-	65,000	0.0%
Maurie Stang	49,107	5,893	-	-	55,000	0.0%
Linda Walters *	40,179	4,821	-	-	45,000	0.0%
Total Non-Executive Directors'	**147,322**	**17,678**	**-**	**-**	**165,000**	
Executive Officers:						
Tara Speranza ***	24,808	2,977	39,064	-	66,849	0.0%
Total Executive Officers	**24,808**	**2,977**	**39,064**	**-**	**66,849**	
TOTAL	**172,129**	**20,655**	**39,064**	**-**	**231,848**	

There were no long term benefits paid to directors and executive officers during 2026 financial year

Details of **directors' and executive officers'** remuneration for the year ended 30 June 2025

2025						
Non-Executive Directors'						
Ronald Shnier	58,559	6,441	-	-	65,000	0.0%
Maurie Stang	49,550	5,450	-	-	55,000	0.0%
Linda Walters *	21,421	2,463	-	-	23,884	0.0%
Susan Pond**	16,609	1,911	-	-	18,520	0.0%
Total Non-Executive Directors'	**146,139**	**16,265**	**-**	**-**	**162,404**	
Total Executive Directors'	**-**	**-**	**-**	**-**	**-**	
TOTAL	**146,139**	**16,265**	**-**	**-**	**162,404**	

There were no long term benefits paid to directors and executive officers during 2025 financial year.

*** Appointed as CEO and CTO on 7 May 2026

** Ceased to be a Director on 27 November 2024

* Appointed to the Board on 20 December 2024



EMPLOYMENT CONTRACTS

Chief Executive Officer (CEO) and Chief Technology Officer (CTO):

The following sets out the key terms of the employment agreement for the CEO and CTO, Dr Tara Speranza.

Contract term:	Appointed on 7 May 2026 Continuous employment until notice is given by either party
Fixed remuneration:	$150,000 per year plus superannuation
Incentives:	On 8 May 2026, Dr Speranza was granted a total of 1,090,000 performance securities, representing approximately 2% of the Company's issued capital on a fully diluted basis, as follows: • 109,000 shares (10%) The remaining 981,000 zero exercise price options (ZEPOs) will be subject to vesting conditions as follows. Vesting conditions are linked to a combination of: • share price performance milestones (between 20 and 30 cents); and • operational milestones, including fundraising, clinical development and potential partnership or licensing outcomes. The ZEPOs will vest over a period of up to four years, subject to the satisfaction of the relevant milestones and Board discretion. The ZEPOs will expire if not exercised by 7 May 2030.
Notice period:	To terminate the employment, Dr Speranza is required to provide Vectus with 3 months written notice. Vectus must provide 3 months written notice.
Resignation or termination:	On resignation, unless the Board determines otherwise: All unvested short term or long term benefits are forfeited. All vested but unexercised benefits are forfeited after 90 days following cessation of employment.
Statutory entitlements:	Annual leave applies in all cases of separation. Long Service applies unless service is under 10 years and she is dismissed for misconduct.
Termination for serious misconduct:	Vectus may immediately terminate employment at any time in case of serious misconduct, and Dr Speranza will only be entitled to payment of fixed remuneration until termination date. Such termination will result in all unvested benefits being forfeited. Treatment of any vested but unexercised benefits will be at the discretion of the Board.

There are no contracts to which a Director is a party or under which a Director is entitled to a benefit .

LINK BETWEEN REMUNERATION AND PERFORMANCE AND STATUTORY PERFORMANCE INDICATORS

The table below shows measures of the group's financial performance over the last five years as required by the Corporations Act 2001. However, these are not necessarily consistent with the measures used in determining the variable amounts of remuneration to be awarded to KMPs. As a consequence, there may not always be a direct correlation between the statutory key performance measures and the variable remuneration awarded.

	2026 $	2025 Re-stated $	2024 Re-stated $	2023 $	2022 $
Profit / (Loss) for the year	1,558,651	(1,862,377)	(2,338,124)	(3,441,789)	(3,969,886)
Basic earnings / (loss) per share	2.87	(3.50)	(4.39)	(7.18)	(11.89)
Dividend payments	-	-	-	-	-
(Decrease) / increase in share price (%)	212.5%	(48.1%)	(82.5%)	(55.3%)	(27.0%)
Total KMP remuneration as percentage of profit / (loss) for the year (%)	15%	(9%)	(7%)	(13%)	(12%)

PERFORMANCE RIGHTS OR OPTIONS

Following rights or options, exercisable into Shares, which has been issued to key management personnel, and have not expired as at the end of financial year:

	Number of options / rights 2026	 2025
Options granted to Maurie Stang, Non-Executive Director	316,000	316,000
Options granted to Tara Speranza, CEO and CTO	784,800	-
Shares were issued to key management personnel:		
Shares issued to Tara Speranza, CEO and CTO	305,200	-

Signed in accordance with a resolution of the directors; pursuant to section 298(2)(a) of Corporations Act 2001 on behalf of the directors.

Dr Ronald Shnier
Non-Executive Chairman

28 August 2026



Auditor's Independence Declaration

UHY
Connect to possibility

UHY Haines Norton
Chartered Accountants
Level 9, 1 York Street
Sydney NSW 2000

GPO Box 4137
Sydney NSW 2001

T + 61 2 9256 6600
E sydney@uhyhnsyd.com.au

uhyhnsydney.com.au

Auditor's Independence Declaration under Section 307C of the *Corporations Act 2001*

To the Directors of Vectus Biosystems Limited

I declare that, to the best of my knowledge and belief, in relation to the audit for the year ended 30 June 2026, there have been:

(i) No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and

(ii) No contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Vectus Biosystems Limited and the entities it controlled during the year.

UHY Haines Norton

Matthew Pope
Partner
Sydney
Dated 28 August 2026

UHY Haines Norton
Chartered Accountants

Financial Statements

For the year ended 30 June 2026



Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the year ended 30 June 2026

	Note	2026 $	2025 Re-stated $
Revenue and other income	3	2,767,048	478,182
Fair value gains on revaluation		204,077	-
Administration and corporate expenses		(770,650)	(948,964)
Finance costs	4	(44,071)	(3,906)
Depreciation and amortisation expense	4	(4,597)	(13,690)
Employee benefits expense and directors' remuneration	4	(405,530)	(518,881)
Occupancy expenses		(10,074)	(30,269)
Research & development	4	(172,997)	(752,929)
Loss on disposal of fixed assets		-	(71,920)
Travel expenses		(4,555)	-
Profit / (Loss) before income tax benefit from continuing operations		**1,558,651**	**(1,862,377)**
Income tax benefit	5	-	-
Net profit / (loss) for the year		**1,558,651**	**(1,862,377)**
Other comprehensive income, net of tax Items that will not be reclassified to profit or loss:		-	-
TOTAL COMPREHENSIVE PROFIT / (LOSS) FOR YEAR, NET OF TAX		**1,558,651**	**(1,862,377)**
Profit / (loss) for the year attributable to: Owners of Vectus Biosystems Limited		1,558,651	(1,862,377)
Total comprehensive profit / (loss) for the year attributable to: Owners of Vectus Biosystems Limited		1,558,651	(1,862,377)
Earnings / (loss) per share	26		
Basic earnings / (loss) per share (cents per share) from continuing operations		2.87	(3.50)
Diluted earnings / (loss) per share (cents per share) from continuing operations		2.81	(3.50)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.



Consolidated Statement of Financial Position

As at 30 June 2026

	Note	2026 $	2025 Re-stated $	2024 Re-stated $
Current assets				
Cash and cash equivalents	6	718,594	250,988	808,969
Advance to supplier		-	71,389	34,000
Investments	7	2,798,071	-	-
Other current assets	8	284,130	527,453	1,034,487
Total current assets		**3,800,795**	**849,830**	**1,877,456**
Non-current assets				
Property, plant and equipment	9	17,106	4,215	182,171
Advance to supplier		-	-	226,507
Total non-current assets		**17,106**	**4,215**	**408,678**
Total assets		**3,817,901**	**854,045**	**2,286,134**
Current liabilities				
Trade and other payables	10	607,307	433,395	213,234
Other current liabilities	11A	351,417	287,168	156,801
Borrowings (insurance premium funding)		43,498	-	-
Provisions	12A	2,070	11,331	164,659
Total current liabilities		**1,004,292**	**731,894**	**534,694**
Non-current liabilities				
Provisions	12B	53	3,384	4,568
Borrowings	13	487,001	200,000	-
Other non-current liabilities	11B	7,783	-	-
Total non-current liabilities		**494,837**	**203,384**	**4,568**
Total liabilities		**1,499,129**	**935,278**	**539,262**
NET ASSET / (LIABILITIES)		**2,318,772**	**(81,233)**	**1,746,872**
Equity				
Issued capital	14	39,172,430	38,368,557	38,368,557
Reserves	25	915,577	878,096	843,823
Accumulated Losses	15	(37,769,235)	(39,327,886)	(37,465,508)
TOTAL EQUITY / (DEFICIT)		**2,318,772**	**(81,233)**	**1,746,872**

The above consolidated statement of financial position should be read in conjunction with the accompanying notes.



Consolidated Statement of Cash Flows

For the year ended 30 June 2026

	Note	2026 $	2025 $
Cash flows from operating activities			
R&D tax offset rebate received		421,554	977,084
Payments to suppliers and employees and net working capital		(1,002,380)	(1,822,044)
Interest received		7,432	18,777
Interest paid		-	(3,905)
Net cash used in operating activities	23(b)	**(573,394)**	**(830,088)**
Cash flows from investing activities			
Disposal of fixed assets		-	101,033
Investment in property, plant and equipment		-	-
Net cash provided by investing activities		**-**	**101,033**
Cash flows from financing activities			
Lease payments		-	(28,926)
Loan borrowings		250,000	200,000
Issue of shares		791,000	-
Net cash provided by financing activities		**1,041,000**	**171,074**
Net increase / (decrease) in cash and cash equivalents		467,606	(557,981)
Cash and cash equivalents at the beginning of the financial year		250,988	808,969
Cash and cash equivalents at the end of the financial year	23(a)	**718,594**	**250,988**

The above consolidated statement of changes in cash flows should be read in conjunction with the accompanying notes.



Consolidated Statement of Changes in Equity

For the year ended 30 June 2026

	Note	Equity $	Accumulated losses $	Reserves $	Total attributable to equity holders of the entity $
Balance at 1 July 2024 (Re-stated)		**38,368,557**	**(37,465,508)**	**843,823**	**1,746,872**
Comprehensive Income					
Profit / (loss) for the year		-	(1,862,377)	-	(1,862,377)
Total comprehensive profit / (loss) for the year		**-**	**(1,862,377)**	**-**	**(1,862,377)**
Transactions with owners					
Shares issued during the year	14	-	-	-	-
Share issue costs	14	-	-	-	-
Movements in share-based payment reserve	25	-	-	34,273	34,273
BALANCE AT 30 JUNE 2025 (Re-stated)		**38,368,557**	**(39,327,886)**	**878,096**	**(81,233)**
Balance at 1 July 2025 (Re-stated)		**38,368,557**	**(39,327,886)**	**878,096**	**(81,233)**
Comprehensive Income					
Profit / (loss) for the year		-	1,558,651	-	1,558,651
Other comprehensive income		-	-	-	-
Total comprehensive profit / (loss) for the year		**-**	**1,558,651**	**-**	**1,558,651**
Transactions with owners					
Shares issued during the year	14	803,873	-	-	803,873
Movements in share-based payment reserve	25	-	-	37,481	37,481
BALANCE AT 30 JUNE 2026		**39,172,430**	**(37,769,235)**	**915,577**	**2,318,772**

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Notes to the Consolidated Financial Statements

For the year ended 30 June 2026

1 / Summary of Significant Accounting Policies

CORPORATE INFORMATION

The financial report of Vectus Biosystems Limited (the Group) for the year ended 30 June 2026 was authorised for issue in accordance with a resolution of the Directors on 26 August 2026. The directors have the power to amend and reissue the financial statements.

Vectus Biosystems Limited (the parent) is a company limited by shares incorporated in Australia whose shares are publicly listed on the Australian Stock Exchange (ASX code: VBS).

The nature of the operations and principal activities of the Group are described in the Directors' Report.

BASIS OF PREPARATION

These general purpose financial statements have been prepared in accordance with the Corporations Act 2001, Australian Accounting Standards and Interpretations of the Australian Accounting Standards Board and International Financial Reporting Standards as issued by the International Accounting Standards Board. The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise.

The financial statements have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

GOING CONCERN

The consolidated profit after tax of the Group for the 2026 financial year amounted to $1,558,651 (2025: re-stated loss $1,862,377) and the net equity as at 30 June 2026 was $2,318,772 (2025: Deficit of $81,233 re-stated). The operating cash burn rate for the financial year ended 30 June 2026 was $573,394 (2025: $830,088).
The cash balance at 30 June 2026 was $718,594 (2025: $250,988). The above matters may give rise to a material uncertainty that may cast significant doubt over the Group's ability to continue as a going concern. Therefore the Group may be unable to realise its assets and discharge its liabilities in the normal course of business at the amounts stated in the financial report. However, the Directors believe that the Group will be able to continue as a going concern due to the following mitigating factors in relation to the material uncertainty.

The Directors have prepared detailed cash flow projections for the period of 12 months from the date of signing this Report.
The Group is dependent on funds received from R&D Tax Incentive, as well as loans, capital raisings, licensing and commercial activities, and shareholders to continue to operate with enough cash on hand for the next 12 months. The Company has the ability to gain additional liquidity through the sale of some tranches of XORTX shares and warrants. The Group demonstrated in previous years its success in raising capital, including in the 2026 financial year. The Directors remain confident that this can be repeated as required to support the Group's continuing activities. As previously announced, the Company is now focusing on the commercialisation of its clinical drug VB0004. Further, in the event insufficient funds are raised to meet the Going Concern principle through the methods mentioned in this note above, the Group will further reduce costs and related party creditors will defer requests for payment so that the Group will be able to continue as a Going Concern.

Consequently, the Group's financial statements have been prepared on a going concern basis, which contemplates the realisation of assets and satisfaction of liabilities and commitments in the normal course of business.
The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities should the Group be unable to continue as a going concern.

CRITICAL ACCOUNTING ESTIMATES

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2.

STATEMENT OF COMPLIANCE

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in a financial report containing relevant and reliable information about transactions, events and conditions. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards.

NEW, REVISED OR AMENDING ACCOUNTING STANDARDS AND INTERPRETATIONS ADOPTED

The consolidated entity has adopted all of the applicable and relevant new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. Management does not currently expect any of the new accounting standards not yet effective to have a material impact on the group, however these will be continued to be monitored ahead of the effective date.

There are no standards that have been issued by the International Accounting Standards Board, not yet adopted by Australia, that needs to be considered or is expected to have any material impact on the financial performance or position of the consolidated entity.

ACCOUNTING POLICIES

a/ Principles of Consolidation

The consolidated financial statements incorporate all of the assets, liabilities and results of the parent (Vectus Biosystems Limited) and the subsidiary (including any structured entities). Subsidiary is the entity the parent controls. The parent controls an entity when it is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. A list of the subsidiaries is provided in Note 19.

The assets, liabilities and results of the subsidiary are fully consolidated into the financial statements of the Group from the date on which control is obtained by the Group. The consolidation of a subsidiary is discounted from the date that control ceases. Intercompany transactions, balances and unrealised gains or losses on transactions between group entities are fully eliminated on consolidation. Accounting policies of the subsidiary has been changed and adjustments made where necessary to ensure uniformity of the accounting policies adopted by the Group.

Equity interests in a subsidiary not attributable, directly or indirectly, to the Group are presented as "non-controlling interests". The Group initially recognises non-controlling interests that are present ownership interests in subsidiaries and are entitled to a proportionate share of the subsidiary's net assets on liquidations at either fair value or at the non-controlling interests' proportionate share of the subsidiary's net assets. Subsequent to initial recognition, non-controlling interests are attributed their share of profit or loss and each component of other comprehensive income. Non-controlling interests are shown separately within the equity section of the statement of financial position and statement of comprehensive income.

b/ Property, Plant and Equipment

Property, plant and equipment are measured on the cost basis and are therefore carried at cost less accumulated depreciation and any accumulated impairment losses. In the event the carrying amount of plant and equipment is greater than its estimated recoverable amount, the carrying amount is written down immediately to its estimated recoverable amount and impairment losses are recognised either in profit or loss or as a revaluation decrease if the impairment losses relate to a revalued asset.

Depreciation

The depreciable amount of all fixed assets is depreciated on a prime cost method over the assets useful life to the company commencing from the time the asset is held ready for use. Depreciation is recognised in the profit and loss.

The depreciation rates used for each class of depreciable assets are:

Class of Fixed Asset	Depreciation Rate
Plant & Equipment	20% - 40%
Fixtures & Fittings	10% - 20%
Office Equipment	20% - 50%

The carrying amount of plant and equipment is reviewed annually by directors to ensure it is not in excess of the recoverable amount from the assets. The recoverable amount is assessed on the basis of the expected net cash flows that will be received from the asset's employment and subsequent disposal. The expected net cash flows have been discounted to their present values in determining recoverable amounts.

c/ Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within the short-term borrowings in current liabilities in the statement of financial position.

d/ Revenue and Other Income

Revenue is measured at the value of the consideration received or receivable.

Interest revenue is recognised using the effective interest rate method, which, for floating rate financial assets, is the rate inherent in the instrument. Dividend revenue is recognised when the right to receive a dividend has been established.

All revenue is stated net of the amount of goods and services tax.

e/ Trade Receivables and Other Receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days.

The consolidated entity has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

f/ Trade Creditors and Other Payables

Trade and other payables represent the liabilities for goods and services received by the company during the reporting period that remain unpaid at the end of the reporting period. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

g/ Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from the ATO is included with other receivables in the statement of financial position.

Cash Flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities are recoverable, or payable to, the ATO are presented as operating cash flows included in receipts from or payments to suppliers.

h/ Employee Benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled within 12 months of the reporting date are recognised in current liabilities in respect of employees' services up to the reporting date and are measured at the amounts expected to be paid when the liabilities are settled.

Other long-term employee benefits

The liability for long service leave not expected to be settled within 12 months of the reporting date is recognised in non-current liabilities, provided there is an unconditional right to defer settlement of the liability. The liability is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on national government bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

Defined contribution superannuation expense

Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

Share-based payment

The fair value of options or share-based payments granted under the Employee Option Plan is recognised as an employee benefit expenses with a corresponding increase in equity. The fair value is measured at grant date and recognised over the period during which the employees become unconditionally entitled to the options or shares.

At each balance sheet date, the entity revises its estimate of the number of options or shares that are expected to vest or become exercisable. The employee benefit expense recognised each period takes into account the most recent estimate. The impact of the revision to original estimates, if any, is recognised in the income statement with a corresponding adjustment to equity.

i/ Lease liabilities

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the consolidated entity's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

j/ Financial Instruments

Financial assets

Financial assets are initially measured at fair value. Transaction costs are included as part of the initial measurement, except for financial assets at fair value through profit or loss. They are subsequently measured at either amortised cost or fair value depending on their classification. Classification is determined based on the purpose of the acquisition and subsequent reclassification to other categories is restricted.

Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the consolidated entity has transferred substantially all the risks and rewards of ownership.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are either: i) held for trading, where they are acquired for the purpose of selling in the short-term with an intention of making a profit; or ii) designated as such upon initial recognition, where they are managed on a fair value basis or to eliminate or significantly reduce an accounting mismatch. Except for effective hedging instruments, derivatives are also categorised as fair value through profit or loss. Fair value movements are recognised in profit or loss.

Interest

Interest is classified as an expense consistent with the balance sheet classification of the related debt or equity instruments.

Financial liabilities

The Group classifies its financial liabilities as measured at amortised cost. The Group does not use derivative financial instruments in economic hedges of currency or interest rate risk.

These financial liabilities include the following items:

Trade payables and other short-term monetary liabilities, which are initially recognised at fair value and subsequently carried at amortised cost using the effective interest method.

Impairment

A financial asset (or a group of financial assets) is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events (a "loss event") having occurred, which has an impact on the estimated future cash flows of the financial asset(s).

In the case of available-for-sale financial assets, a significant or prolonged decline in the market value of the instrument is considered to constitute a loss event. Impairment losses are recognised in profit or loss immediately. Also, any cumulative decline in fair value previously recognised in other comprehensive income is reclassified into profit or loss at this point.

In the case of financial assets carried at amortised cost, loss events may include: indications that the debtors or a group of debtors are experiencing significant financial difficulty, default or delinquency in interest or principal payments; indications that they will enter bankruptcy or other financial reorganisation; and changes in arrears or economic conditions that correlate with defaults.

For financial assets carried at amortised cost (including loans and receivables), a separate allowance account is used to reduce the carrying amount of financial assets impaired by credit losses. After having taken all possible measures of recovery, if management establishes that the carrying amount cannot be recovered by any means, at that point the written-off amounts are charged to the allowance account or the carrying amount of impaired financial assets is reduced directly if no impairment amount was previously recognised in the allowance account.

When the terms of financial assets that would otherwise have been past due or impaired have been renegotiated, the Group recognised the impairment for such financial assets by taking into account the original terms as if the terms have not been renegotiated so that the loss events that have occurred are duly considered.

Derecognition

Financial assets are derecognised when the contractual rights to receipt of cash flows expire or the asset is transferred to another party whereby the entity no longer has any significant continuing involvement in the risks and benefits associated with the asset. Financial liabilities are derecognised when the related obligations are discharged, cancelled or have expired. The difference between the carrying amount of the financial liability extinguished or transferred to another party and the fair value of consideration paid, including the transfer of non-cash assets or liabilities assumed, is recognised in profit or loss.

k/ Issued Capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of the new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

l/ Right-of-use assets

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight line basis over the unexpired period of lease or the estimated useful life of the asset, whichever is shorter. Where the consolidated entity expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of-use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The consolidated entity has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments of these are expensed to profit or loss as incurred.

m/ Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is current when it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within twelve months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability at least twelve months after the reporting period. All other assets are classified as non-current.

A liability is current when; it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within twelve months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. All other liabilities are classified as non-current.

n / Intangible Assets

Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period.

Research and development

Research costs are expensed in the period in which they are incurred. Development costs are capitalised when it is probable that the project will be a success considering its commercial and technical feasibility; the consolidated entity is able to use or sell the asset; the consolidated entity has sufficient resources; and intent to complete the development and its costs can be measured reliably. Capitalised development costs are amortised on a straight-line basis over the period of their expected benefit.

Patents and trademarks

Patents are in relation to research and are not capitalised, the costs associated with patents have been included as an expense.

o/ Provisions

Provisions are recognised when the Group has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.

Provisions are measured using the best estimate of the amounts required to settle the obligation at the end of the reporting period.

p/ Government Grants

Government grants are recognised at fair value where there is reasonable assurance that the grant will be received and all grant conditions will be met. Grants relating to expense items are recognised as income over the periods necessary to match the grant to the costs it is compensating. Grants relating to assets are credited to deferred income at fair value and are credited to income over the expected useful life of the asset on a straight-line basis.

q/ Comparative Figures

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

Where the Group retrospectively applies an accounting policy, makes a retrospective restatement or reclassifies items in its financial statements, an additional (third) statement of financial position as at the beginning of the preceding period in addition to the minimum comparative financial statements is presented.

r/ Earnings per share

Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to equity holders of the company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the year, adjusted for bonus elements in ordinary shares issued during the year.

Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

s/ Borrowings

Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method if the impact is material to the financial report. Where there is an unconditional right to defer settlement of the liability for at least 12 months after the reporting date, the loans or borrowings are classified as non-current.

t/ Income tax

Income tax on the profit or loss for the year comprises current and deferred tax. Income tax is recognised in the income statement except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity.

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantially enacted at the balance sheet date, and any adjustment to tax payable in respect of previous years.

Deferred tax is accounted for using the balance sheet liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes, the initial recognition of assets or liabilities that affect neither accounting nor taxable profit, and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future.

The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date.

A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilised. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realised.

Tax Consolidation

The company and all its wholly-owned Australian resident entities have entered into a tax consolidated group under Australian taxation law.

The company is the head entity in the tax-consolidated group comprising all the Australian wholly-owned subsidiaries set out in note 19. The head entity recognises all of the current and deferred tax assets and liabilities of the tax consolidated group (after elimination of intragroup transactions).

u/ Recoverable amount of non-current assets

The carrying amounts of non-current assets valued on the cost basis are reviewed to determine whether they are in excess of their recoverable amount at reporting date. If the carrying amount of a non-current asset exceeds its recoverable amount, the asset is written down to the lower amount. The write-down is expensed in the reporting period in which it occurs.

Where a group of assets working together supports the generation of cash inflows, recoverable amount is assessed in relation to that group of assets. In assessing recoverable amounts of non-current assets, the relevant cash flows have been discounted to their present value.

2 / Critical Accounting Judgements, Estimates and Assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results.

The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Employee benefits provision

As discussed in note 1, the liability for employee benefits expected to be settled more than 12 months from the reporting date are recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

3 / Revenue and other Income

	2026 $	2025 $
R&D tax offset rebate	209,554	461,177
Interest income	7,432	18,767
Other income (refer note*)	2,550,737	-
Other revenue	(675)	(1,762)
	2,767,048	**478,182**
* Other income includes net income from sale of the Company's VB4-P5 Renal Small Molecule Compound to XORTX Therapeutics Inc.		
Consideration received in the form of shares and pre-funded warrants valued at fair market value at the date of closure being 14 April 2026	2,593,994	-
Professional and consulting expenses incurred	(43,257)	-
NET OTHER INCOME	**2,550,737**	**-**

4 / Profit / (Loss) from Ordinary Activities

	2026 $	2025 $
EXPENSES		
Depreciation and amortisation expense		
Depreciation of property, plant and equipment	4,597	13,690
	4,597	**13,690**
Employment benefits and directors' remuneration		
Base salary and fees	351,971	476,469
Superannuation and statutory oncosts	15,590	33,705
Share based payments	1,290	28,582
Other employee expenses	49,270	6,316
Transfers from employee entitlements provisions	(12,591)	(26,191)
	405,530	**518,881**
Finance Costs		
Interest on Directors' loan	42,607	1,665
Other finance costs	1,464	2,241
	44,071	**3,906**
Research & Development expense		
Research and Development expense (2025: re-stated)	978	630,056
Patent costs	172,019	122,873
	172,997	**752,929**

5 / Income Tax

	2026 $	2025 Re-stated $
a/ Income tax expense		
The prima facie income tax benefit on pre-tax accounting loss reconciles to the income tax benefit in the financial statements as follows:		
PROFIT / (LOSS) FOR YEAR BEFORE INCOME TAX BENEFIT	**1,558,651**	**(1,862,377)**
Income tax benefit calculated at 30%	467,595	(558,713)
Temporary differences and tax losses not recognised	(415,973)	426,029
Permanent differences		
R&D grant included in P&L not assessable	(62,866)	(138,353)
R&D expenses not deductible	-	260,755
Share based payments	11,244	10,282
INCOME TAX BENEFIT	**-**	**-**
b/ Deferred tax balances recognised		
Deferred tax assets		
Accruals	79,000	-
Deferred tax liabilities		
Investments	(61,223)	-
Prepayments	(17,777)	-
NET DEFERRED TAX BALANCES RECOGNISED	**(79,000)**	**-**
Deferred tax balances not recognised		
Deferred tax assets relating to tax losses		
Revenue tax losses available for offset against future tax income	6,022,666	6,531,763
NET DEFERRED TAX ASSET NOT RECOGNISED IN RESPECT OF TAX LOSSES	**6,022,666**	**6,531,763**

5 / Income Tax cont'd

	2026 $	2025 Re-stated $
Deferred tax assets relating to temporary differences		
Accruals	23,911	65,150
Other liabilities	637	4,415
Patents	137,449	144,571
Lease	41	-
Prepayments	-	(26,671)
NET DEFERRED TAX ASSET NOT RECOGNISED IN RESPECT OF TEMPORARY DIFFERENCES	**162,038**	**187,465**

Relevance of tax consolidation to the consolidated entity

Legislation to allow groups comprising a parent entity and its Australian wholly-owned subsidiary, to elect to consolidate and be treated as a single entity for income tax purposes ('the tax consolidation system') was substantively enacted on 21 October 2002. The company and its wholly-owned Australian resident entity have been consolidated for tax purposes under this legislation.

6 / Cash and Cash Equivalents

	2026 $	2025 $
Cash on Hand	-	-
Cash at Bank and Term Deposits	718,594	250,988
	718,594	**250,988**

7 / Investments

XORTX shares	510,722	-
XORTX pre-funded warrants	2,287,349	-
	2,798,071	**-**

XORTX shares and pre-funded warrants represents the consideration received for the sale of Company's VB4-P5 Renal Small Molecule Compound. These instruments were originally valued at fair market value at the date of closure being 14 April 2026 and subsequently adjusted to the market value of the shares at 30 June 2026.

8 / Other Current Assets

	2026 $	2025 $
Prepayments	59,257	88,905
R&D Grant Receivable	208,000	420,000
Inventory	-	978
Goods and Services Tax and other receivables	16,873	17,570
	284,130	**527,453**

The carrying amounts of the group's other current assets are a reasonable approximation of their fair values.

9 / Property, Plant and Equipment

Plant and Equipment	15,698	15,698
Less: Accumulated depreciation	(14,622)	(11,483)
	1,076	**4,215**
Office Equipment	69,358	69,358
Less: Accumulated depreciation	(69,358)	(69,358)
	-	**-**
Right-of-use asset	17,487	-
Less: Accumulated depreciation	(1,457)	-
	16,030	-
	17,106	**4,215**

9 / Property, Plant and Equipment cont'd

	Right-of-use asset	Plant and Equipment	Office Equipment	Total
Reconciliations of the written down values at the beginning and end of the current financial year are set out below.				
Balance at 1 July 2025	-	4,216	-	4,216
Additions	17,487	-	-	17,487
Disposals	-	-	-	-
Depreciation	(1,457)	(3,140)	-	(4,597)
BALANCE AT 30 JUNE 2026	**16,030**	**1,076**	**-**	**17,106**
Balance at 1 July 2024	-	178,979	3,192	182,171
Additions	-	-	-	-
Disposals	-	(163,656)	(610)	(164,266)
Depreciation	-	(11,108)	(2,582)	(13,690)
BALANCE AT 30 JUNE 2025	**-**	**4,215**	**-**	**4,215**

10 / Current Trade and Other Payables

	2026 $	2025 Re-stated $
Trade creditors	600,657	429,995
PAYG withholding payable	6,650	3,400
	607,307	**433,395**

The carrying amount of the Group's current trade and other payables are a reasonable approximation of their fair values.

11 / Other current and non-current liabilities

	2026 $	2025 $
a/ Other current liabilities		
Accrued expenses*	343,034	287,168
Lease liability	8,383	-
	351,417	**287,168**
b/ Other non-current Liabilities		
Lease liability	7,783	-
	7,783	**-**
*Accrued expenses include:		
Accrued Directors' fees	287,885	122,885
Accrued R&D and Patent expenses	16,000	120,000
Other accruals	39,149	44,283
	343,034	**287,168**

The carrying amount of the Group's other current and non-current liabilities are a reasonable approximation of their fair values.

12 / Provisions

	2026 $	2025 $
a/ Current		
Provision for Annual Leave	2,070	11,331
Provision for Long Service Leave	-	-
	2,070	**11,331**
b/ Non-Current		
Provision for Long Service Leave	53	3,384
	53	**3,384**

The carrying amount of the Group's provisions are a reasonable approximation of their fair values.

13 / Borrowings

	2026 $	2025 $
Unsecured loans from Directors	487,001	200,000
Refer to 'Transactions with Directors and Director related entities' in Directors' Report. Interest is payable at ATO benchmark rates. This loan can be repaid, without penalty, subject to Board approval, if the Group secures alternative funding. The drawdown of the loan is to be repaid from future receipts from the ATO of research and development (R&D) cash-back or from other funds received.		
	487,001	**200,000**

14 / Issued Capital

	2026 Number of Shares	2025 Number of Shares	2026 $	2025 $
Ordinary shares - fully paid (no par value)	61,690,348	53,278,312	39,172,430	38,368,557
	61,690,348	53,278,312	39,172,430	38,368,557
Movements in ordinary share capital of Vectus Biosystems Limited				
Balance at beginning of the year	53,278,312	53,210,521	38,368,557	38,368,557
Share placement	7,910,000	-	791,000	-
Shares issued to KMP	109,000	-	12,873	-
Other shares issued during the year	393,036	67,791	-	-
	61,690,348	53,278,312	39,172,430	38,368,557
Transaction costs relating to share issues	-	-	-	-
BALANCE AT END OF YEAR	**61,690,348**	**53,278,312**	**39,172,430**	**38,368,557**

For the purposes of these disclosures, the Group considers its capital to comprise its ordinary share capital and accumulated retained earnings. Neither the share based payments reserve nor the translation reserve is considered as capital.

Capital Risk Management

When managing capital, management's objective is to ensure the entity continues as a going concern as well as to maintain optimal returns to shareholders and benefits for other stakeholders. Management also aims to maintain a capital structure that ensures the lowest cost of capital available to the entity.

Management are constantly adjusting the capital structure to take advantage of favourable costs of capital or high returns on assets. As the market is constantly changing, management may change the amount of dividends to be paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

The capital risk management policy remains unchanged from the 30 June 2025 Annual Report.

15 / Accumulated losses

	2026 $	2025 Re-stated $
Accumulated loss at the beginning of the financial year	(39,327,886)	(37,465,509)
Profit / (loss) after income tax expense for the year	1,558,651	(1,862,377)
ACCUMULATED LOSS AT THE END OF THE FINANCIAL YEAR	**(37,769,235)**	**(39,327,886)**

16 / Related party disclosures

a/ Subsidiary

Vectus Biosystems Limited has a 100% interest in Accugen Pty Limited.

b/ Key management personnel

Disclosures relating to key management personnel are set out in note 17.

16 / Related party disclosure cont'd

c/ Transactions with related parties

A number of specified directors, or their personally-related entities, hold positions in other entities that result in them having control or significant influence over the financial or operating policies of those entities.

Details of these transactions and outstanding balances are shown below:

	2026 $	2025 $
Regional Corporate Services Pty Ltd		
Corporate and administration services	145,263	233,520
Current payables	373,229	240,734
Maurie Stang is a director and shareholder of Regional Corporate Services Pty Ltd.		
Loan from Maurie Stang, Non-Executive Deputy Chairman		
Loan borrowing	250,000	200,000
Loan repaid	-	-
Interest on loan capitalised	37,001	-
Outstanding balance	487,001	200,000
Balances outstanding to Directors		
Directors' fees payable to Maurie Stang	100,375	45,375
Directors' fees payable to Ronald Shnier	118,625	53,625
Directors' fees payable to Linda Walters	68,885	23,885

17 / Key management personnel

a/ The Directors and key management personnel of Vectus Biosystems Limited during the year were:

Ronald Shnier

Maurie Stang

Linda Walters

Tara Speranza Appointed as CEO and CTO on 7 May 2026

17 / Key management personnel cont'd

b/ The aggregate compensation made to key management personnel of the consolidated entity is set out below:

	2026 $	2025 $
Short-term employee benefits	172,129	146,139
Post-employment benefits	20,655	16,265
Share-based payments	39,064	-
	231,848	**162,404**

Further disclosures relating to the key management personnel are set out in remuneration report in the Directors' Report.

18 / Commitments

a/ Lease commitments - operating

Committed at the reporting date but not recognised as liabilities:

	2026 $	2025 $
Within one year	-	7,550
One to five years	-	-
	-	**7,550**

b/ Operating commitments

Committed at the reporting date but not recognised as liabilities, payable:

	2026 $	2025 $
Research and development expenses		
Within one year	-	23,769
One to five years	-	-
	-	**23,769**

c/ Capital expenditure commitments

There are no capital expenditure commitments at the end of the financial year.

19 / Interest in subsidiary

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiary in accordance with the accounting policy described in note 1.

Name	Principal place of business/ Country or incorporation	Ownership Interest 2026 / %	Ownership Interest 2025 / %
Accugen Pty Limited	Australia	100%	100%

20 / Subsequent events

There have been no matters or circumstances, which have arisen since 30 June 2026 that have significantly affected or may significantly affect:

a/ the operations, in financial years subsequent to 30 June 2026, of the Group; or

b/ the results of those operations; or

c/ the state of affairs, in the financial years subsequent to 30 June 2026, of the Group.

21 / Remuneration of auditors

	2026 $	2025 $
During the financial year the following fees were paid or payable for services provided by UHY Haines Norton, Chartered Accountants.		
Audit Services - UHY Haines Norton		
Audit and review of financial statements	56,000	78,000
	56,000	**78,000**

22 / Parent entity information

	2026 $	2025 $
Profit / (Loss) after income tax	1,570,802	(1,750,749)
Total comprehensive profit / (loss)	1,570,802	(1,750,749)
Total current assets	2,776,623	2,023,446
Total assets	5,064,591	2,028,661
Total current liabilities	978,820	821,886
Total liabilities	1,473,656	1,025,270
Equity		
Issued capital (net of share issue cost)	39,172,430	38,368,557
Convertible notes	-	-
Reserves	915,577	878,096
Accumulated losses	(36,497,072)	(38,243,263)
TOTAL EQUITY	**3,590,935**	**1,003,391**

Guarantees entered into by the parent entity in relation to the debts of its subsidiary
The parent entity has not entered into guarantee agreement on behalf of its subsidiary.

Operating commitments and Contingent liabilities
Operating commitments and contingent liabilities of the parent entity as at the reporting date are same as of the Group disclosed in note 18 and 28 respectively.

Capital Commitments - Property, plant and equipment
The parent entity had no capital commitments for property, plant and equipment as at 30 June 2026 and 30 June 2025.

Significant accounting policies
The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 1, with exception of the investment in subsidiary that is accounted for at cost.

23 / Notes to Cash Flow Statements

a/ Reconciliation of cash

For the purposes of the statement of cash flows, cash includes cash on hand and in banks and investments in money market instruments, net of outstanding bank overdrafts. Cash at the end of the financial year as shown in the statement of cash flows is reconciled in the related items in the statement of financial position as follows:

	2026 $	2025 $
Cash at bank and on hand	718,594	250,988
	718,594	**250,988**

	2026 $	2025 Re-stated $
b/ Reconciliation of operating profit / (loss) after income tax to net cash flows from operating activities		
Operating profit / (loss) after income tax	1,558,651	(1,862,377)
Non-cash/non-operating items included in profit and loss		
Depreciation and amortisation	4,597	13,690
Loss on disposal of fixed assets	-	71,920
Non-cash income	(2,798,071)	-
Share based payments	50,766	34,273
Change in employee entitlement provision	(12,591)	(154,512)
Interest capitalised	42,607	-
Changes in assets and liabilities		
(Increase) / Decrease in other assets	308,246	507,034
Increase / (Decrease) in trade and other payables	217,411	344,399
Increase / (Decrease) in other liabilities	54,989	215,485
NET CASH USED IN OPERATING ACTIVITIES	**(573,395)**	**(830,088)**

23 / Notes to Cash Flow Statements cont'd

	Lease Liability
c/ Changes in liabilities arising from financing activities	
Balance at 1 July 2025	-
Interest	-
Payments	-
BALANCE AT 30 JUNE 2026	**-**
Balance at 1 July 2024	28,927
Interest	709
Payments	(29,636)
BALANCE AT 30 JUNE 2025	**-**

24 / Operating Segments

The Consolidated Entity operates in one segment, being pharmaceutical research and development. This is the basis on which internal reports are provided to the Directors for assessing performance and determining the allocation of resources within the Consolidated Entity.

25 / Reserves

	2026 $	2025 $
Share based payments reserve		
Balance at beginning of financial year	878,096	843,823
Share based payments during the year allocated to:		
Employees and consultant (recognised as expense - refer note 4)	11,288	34,273
Key management personnel	26,193	-
Utilised for share issue	-	-
BALANCE AT END OF FINANCIAL YEAR	**915,577**	**878,096**
TOTAL RESERVES	**915,577**	**878,096**

25 / Reserves cont'd

	2026 $	2025 $
Particulars of options or rights granted over unissued shares		
Weighted average remaining contractual life	2.81 years	1.67 years
Range of exercise prices	NIL	NIL
Options or rights on issue		
Employees and consultants	55,019	251,855
Key Management Personnel (KMP)	1,100,800	316,000
	1,155,819	**567,855**
Options or rights granted during the year (Details noted below*)		
Employees and consultants	-	75,000
Key Management Personnel (KMP)	1,090,000	-
	1,090,000	**75,000**
Shares issued as a result of exercise of options or rights (Details noted below**)		
Employees and consultants	196,836	67,791
Key Management Personnel (KMP)	305,200	-
	502,036	**67,791**
Options or rights expired or forfeited during the year		
Employees and consultants	-	-
Key Management Personnel (KMP)	-	-
	-	**-**

25 / Reserves cont'd

*** Details of options or rights granted during the year**

	2026 Granted to KMP	2025 Granted to Employees & Consultant
Number of options	981,000	75,000
Exercise price	NIL	NIL
Expiry date	7/5/2030	1/4/2026
Grant date	8/5/2026	1/4/2025
Dividend	NIL	NIL
Market price at grant date	$0.13	$0.08
Valuation price	$0.13	$0.08

Valuation of options granted to employees was on the basis of market price at grant date.

**** Details of shares issued as a result of exercise of options or rights**

	2026 Issued to Employees	2026 Issued to Employees	2026 Issued to Consultant	2026 Issued to Consultants	2026 Issued to Employees	2026 Issued to KMP
Number of options	55,019	50,000	25,000	25,000	41,817	196,200
Exercise price	NIL	NIL	NIL	NIL	NIL	NIL
Expiry date	17/7/2025	4/12/2025	4/12/2025	23/12/2025	13/5/2026	26/6/2026
Market price at exercise date	$0.04	$0.17	$0.17	$0.18	$0.12	$0.13
Original valuation price	$0.26	$0.08	$0.08	$0.26	$0.26	$0.13

	2025 Issued to Consultant	2025 Issued to Consultant	2025 Issued to Employees
Number of options	25,000	25,000	17,791
Exercise price	NIL	NIL	NIL
Expiry date	4/10/2024	12/3/2025	4/10/2024
Market price at exercise date	$0.08	$0.08	$0.08
Original valuation price	$0.26	$0.26	$0.49

26 / Earnings / (Loss) per share

	2026 $	2025 Re-stated $
Basic earnings / (loss) per share (cents per share)	2.87	(3.50)
Diluted earnings / (loss) share (cents per share)	2.81	(3.50)
Profit / (Loss) used to calculate basic earnings / (loss) per share	1,558,651	(1,862,377)
Profit / (Loss) used to calculate diluted earnings / (loss) per share	1,558,651	(1,862,377)
Weighted average number of ordinary shares used to calculate basic earnings / (loss) per share	54,216,366	53,249,660
Weighted average number of ordinary shares used to calculate diluted earnings / (loss) per share*	55,372,185	53,249,660
Options and rights eligible for conversion into ordinary shares in future		
Options	1,155,819	567,855
Convertible notes	-	-
	1,155,819	**567,855**

*Weighted average number of shares including convertible note options and other options are not included because they were anti-dilutive in 2025 financial year.

27 / Financial instruments disclosures

a/ Capital

The Group considers its capital to comprise its ordinary share capital and accumulated retained earnings. In managing its capital, the Group's primary objective is to ensure its continued ability to provide a consistent return for its equity shareholders through a combination of capital growth and distributions. In order to achieve this objective, the Group seeks to maintain a sufficient funding base to enable the Group to meet its working capital and strategic investment needs. In making decisions to adjust its capital structure to achieve these aims, either through new share issues or debt, the Group considers not only its short-term position but also its long-term operational and strategic objectives.

b/ Financial instrument risk exposure and management:

In common with all other businesses, the Group is exposed to risks that arise from its use of financial instruments. This note describes the Group's objectives, policies and processes for managing those risks and the methods used to measure them.

Further quantitative information in respect of these risks is presented throughout these financial statements. The Group is exposed to market risks arising from its holdings in listed securities and related unlisted warrants.

27 / Financial instruments disclosures cont'd

c/ Principal financial instruments:

The principal financial instruments used by the Group, from which financial instrument risks arise, are:

Cash at bank;

R&D Rebate receivable;

Deposits and bonds;

Loan from Directors; and

Trade and other payables.

d/ General objectives, policies and processes

The Board has overall responsibility for the determination of the Group's risk management objectives and policies and has the responsibility for designing and operating processes that ensure the effective implementation of the objectives and policies to the Group's finance function. The Board receives monthly reports through which it reviews the effectiveness of the processes put in place and the appropriateness of the objectives and policies it sets.

The overall objective of the board is to set policies that seek to reduce risk as far as possible without unduly affecting the Group's competitiveness and flexibility. Further details regarding these policies are set out below:

i/ Credit risk:

Credit risk arises principally from the Group's cash and term deposits. It is the risk that the counterparty fails to discharge its obligation in respect of the instrument.

The maximum exposure to credit risk at balance sheet date is as follows:

	2026 $	2025 $
Cash in banks and term deposits	718,594	250,988

ii/ Liquidity risk:

Liquidity risk arises from the Group's management of working capital and the finance charges and principal repayments on its debt instruments. It is the risk that the Group will encounter difficulty in meeting its financial obligations as they fall due.

The Group's policy is to ensure that it will always have sufficient cash to allow it to meet its liabilities when they become due. To achieve this aim, it seeks to maintain cash balances (or agreed facilities) to meet expected requirements for a period of at least 45 days.

The Board receives cash flow projections on a monthly basis as well as information regarding cash balances. As stated in note 1 (Going Concern paragraphs), the Group expected to have sufficient liquid resources to meet its obligations under all reasonable circumstances.

27 / Financial instruments disclosures cont'd

Maturity analysis of financial assets and liability based on management's expectations

The risk implied from the values shown in the table below, reflects a balanced view of cash inflows and outflows. Trade payables and other financial liabilities mainly originate from the financing of assets used in our ongoing operations such as property, plant, equipment and investments in working capital (e.g., trade receivables and inventories). These assets are considered in the Group's overall liquidity risk.

Maturity Analysis - 2026	Cash Flows $	< 1 year $	1-3 years $	Total $	Carrying amount $
Financial assets					
Cash and cash equivalents	718,594	718,594	-	718,594	718,594
TOTAL	**718,594**	**718,594**	**-**	**718,594**	**718,594**
Financial liabilities					
Trade Creditors	607,307	607,307	-	607,307	607,307
Accruals	343,035	343,035	-	343,035	343,035
Loans	528,883	528,883	-	528,883	487,001
TOTAL	**1,479,225**	**1,479,225**	**-**	**1,479,225**	**1,437,343**
NET MATURITY	**(760,631)**	**(760,631)**	**-**	**(760,631)**	**(718,749)**

Maturity Analysis - 2025					
Financial assets					
Cash and cash equivalents	250,988	250,988	-	250,988	250,988
TOTAL	**250,988**	**250,988**	**-**	**250,988**	**250,988**
Financial liabilities					
Trade Creditors	433,395	433,395	-	433,395	433,395
Accruals	287,168	287,168	-	287,168	287,168
Loans	217,200	217,200	-	217,200	200,000
TOTAL	**937,763**	**937,763**	**-**	**937,763**	**920,563**
NET MATURITY	**(686,775)**	**(686,775)**	**-**	**(686,775)**	**(669,575)**

27 / Financial instruments disclosures cont'd

iii/ Interest rate risk:

The Group's exposure to fluctuations in interest rates that are inherent in financial markets arise predominantly from assets and liabilities bearing variable interest rates.

The company's exposure to interest rate risk and the effective weighted average interest rate for classes of financial assets and financial liabilities is set out below:

2026	Weighted average rates %	Floating rates $	Fixed rates $	Non-Interest bearing $	Total $
Financial assets					
Cash and cash equivalents	3.0%	718,594	-	-	718,594
TOTAL		**718,594**	**-**	**-**	**718,594**
Financial liabilities					
Trade Creditors	0.0%	-	-	607,307	607,307
Other payables and accruals	0.0%	-	-	343,035	343,035
Borrowings	8.6%	-	487,001	-	487,001
TOTAL		**-**	**487,001**	**950,342**	**1,437,343**
NET FINANCIAL ASSETS (LIABILITIES)		**718,594**	**(487,001)**	**(950,342)**	**(718,749)**

2025					
Financial assets					
Cash and cash equivalents	2.0%	250,988	-	-	250,988
TOTAL		**250,988**	**-**	**-**	**250,988**
Financial liabilities					
Trade Creditors	0.0%	-	-	433,395	433,395
Other payables and accruals	0.0%	-	-	287,168	287,168
Borrowings	8.6%	-	200,000	-	200,000
TOTAL		**-**	**200,000**	**720,563**	**920,563**
NET FINANCIAL ASSETS (LIABILITIES)		**250,988**	**(200,000)**	**(720,563)**	**(669,575)**

27 / Financial instruments disclosures cont'd

The following sensitivity analysis is based on the interest rate risk exposure in existence at the balance sheet date. The analysis assumes all other variables remain constant.

2026	Carrying amount	+0.5% interest Profit & Loss	-0.5% interest Profit & Loss
Sensitivity analysis			
Cash at bank	718,594	3,593	(3,593)
Term deposits	-	-	-
		3,593	(3,593)
Tax charge of 30%		(1,078)	1,078
Post tax profit increase / (decrease)		2,515	(2,515)

2025			
Cash at bank	250,988	1,255	(1,255)
Term deposits	-	-	-
		1,255	(1,255)
Tax charge of 30%		(376)	376
Post tax profit increase / (decrease)		878	(878)

28 / Contingent Liabilities

There are no contingent liabilities of the company or the Group.

29 / Correction of errors and restatements

In 2021 the Company signed a work order with Syneos Health to conduct research activities. Vectus was required to make an initial payment as a deposit upon execution of the work order. The Company recorded these deposits as Contract Research expenses, whereas the amount should have been recorded as a deposit to offset against the final invoices at the end of the project.

In 2024 the Company paid a deposit to Asymchem Laboratories to conduct stability studies. The Company recorded these deposits as Contract Research expenses, whereas the amount should have been recorded as a deposit to offset against the final invoices at the end of the project.

These errors have been corrected by restating each of the affected financial statement line items for prior periods. The following table summarises the impacts on the Group's consolidated financial statements.

	Reported $	Adjustment $	Restated $
Consolidated statement of financial position as at 30 June 2024			
Current assets	1,843,456	34,000	1,877,456
Non-current assets	182,171	226,507	408,678
Total Assets	2,025,627	260,507	2,286,134
Net Asset / (liabilities)	1,486,365	260,507	1,746,872
Accumulated losses	(37,726,015)	260,507	(37,465,508)
Consolidated statement of financial position as at 30 June 2025			
Current assets	778,441	71,389	849,830
Total Assets	782,656	71,389	854,045
Current liabilities	835,894	(104,000)	731,894
Total liabilities	1,039,278	(104,000)	935,278
Net Asset / (liabilities)	(256,622)	175,389	(81,233)
Accumulated losses	(39,503,275)	175,389	(39,327,886)
Consolidated statement of profit or loss and other comprehensive income for the year ended 30 June 2025			
Research & development expenses	667,811	85,118	752,929
Total comprehensive loss	(1,777,259)	(85,118)	(1,862,377)
Basic and diluted loss per share (cents per share) from continuing operations	(3.34)	(0.16)	(3.50)



Consolidated Entity Disclosure Statement

For the year ended 30 June 2026

Name of entity	Type of entity	Trustee, partner or participant in JV	% of share capital	Place of incorporation	Australian resident or foreign resident	Foreign jurisdiction(s) of foreign residents
Parent entity						
Vectus Biosystems Limited	Body corporate	N/A	N/A	Australia	Australian	N/A
Controlled entity of Vectus Biosystems Limited						
Accugen Pty Limited	Body corporate	N/A	100%	Australia	Australian	N/A

The ultimate controlling entity of the Group is Vectus Biosystems Limited. The Group's consolidated entity disclosure statement as at 30 June 2026 has been prepared in accordance with Section 295 (3A) of the Corporations Act and includes information for each entity that was part of the consolidated entity as at the end of the financial year in accordance with AASB 10 Consolidated Financial Statements



Directors' Declaration

In the opinion of the Directors:

1. the attached financial statements and notes that are set out on pages 20 to 55 and remuneration disclosures that are contained in the Remuneration Report in the Directors' Report comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
2. the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;
3. the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 30 June 2026 and of its performance for the financial year ended on that date;
4. there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and
5. the consolidated entity disclosure statement on page 56 is true and correct.

The directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the Board of Directors

Dr Ronald Shnier
Non-Executive Chairman

28 August 2026

Independent Auditor’s Report

UHY Haines Norton
Chartered Accountants
Level 9, 1 York Street
Sydney NSW 2000

GPO Box 4137
Sydney NSW 2001

T + 61 2 9256 6600
E sydney@uhyhnsyd.com.au

uhyhnsydney.com.au

Independent Auditor's Report

To the Members of Vectus Biosystems Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Vectus Biosystems Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2026, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, notes to the financial statements, including material accounting policies, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

i. giving a true and fair view of the Group's financial position as at 30 June 2026 and of its financial performance for the year ended on that date;
ii. complying with Australian Accounting Standards and the Corporations Regulations 2001; and
iii. the consolidated entity disclosure statement required by section 295(3A) of the Corporations Act 2001 being true and correct.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 of the financial report, which indicates the Group had net cash outflows from operating activities for the financial year ended 30 June 2026 of $573,394. As stated in Note 1, these events or conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern and, therefore, whether it will realise its assets and discharge its liabilities in the normal course of business, and at the amounts stated in the financial report. Our opinion is not modified in respect of this matter.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current year. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Except for the matter described in the Material Uncertainty Related to Going Concern section, we have determined that there are no other key audit matters to communicate in our report.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2026, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon, with the exception of the Remuneration Report and our related assurance opinion.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of:

a) the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* (other than the consolidated entity disclosure statement); and
b) the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001*, and

for such internal control as the directors determine is necessary to enable the preparation of:

i. the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
ii. the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

UHY
Connect to possibility

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the financial report. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial report of the current year and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 12 to 17 of the directors' report for the year ended 30 June 2026.

In our opinion, the Remuneration Report of Vectus Biosystems Limited for the year ended 30 June 2026 complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

UHY Haines Norton

Matthew Pope
Partner
Sydney
Dated 28 August 2026

UHY Haines Norton
Chartered Accountants

Australian Securities Exchange (ASX) Additional Information



Australian Securities Exchange (ASX) Additional Information

Additional information required by the ASX Listing Rules, and not disclosed elsewhere in this Annual Report, is detailed below. This information was prepared based on Vectus Biosystems Limited's Share Registry information.

SECURITY HOLDER INFORMATION

Distribution of Shareholders

Analysis of the fully paid ordinary shares by holding as at 8 September 2026:

Spread of Holdings	Number of Holders	Ordinary shares	% of Total Issued Capital
1 – 1,000	77	39,813	0.06
1,001 – 5,000	168	387,999	0.62
5,001 – 10,000	57	439,525	0.71
10,001 – 100,000	188	7,219,010	11.61
100,001 – and over	79	54,096,704	87.00
TOTALS	**569**	**62,183,051**	**100.00**

On 8 September 2026 there were 207 shareholders holding less than a marketable parcel of $500 worth of shares at a share price of $0.155.

Statement of Shareholdings as at 8 September 2026

The names of the 20 largest holders of fully paid ordinary shares are listed below:

#	Shareholder	Number of Shares	% Holding
1	Kefford Holdings Pty Ltd <The Kefford Family A/C>	6,587,623	10.59
2	J B Toro Pty Ltd	4,060,000	6.53
3	Spinite Pty Ltd	4,035,773	6.49
4	Ajjika Technology Pty Limited <The Ajjika A/C>	3,200,000	5.15
5	Bernard Stang	2,852,500	4.59
6	J P Morgan Nominees Australia Pty Limited	2,705,329	4.35
7	Maurie Stang	2,601,952	4.18
8	Energy Trading Systems Pty Ltd <The MPF A/C>	2,562,500	4.12
9	Towns Corporation Pty Ltd <PAE Family A/C>	1,765,750	2.84
10	Gleneagle Securities Nominees Pty Limited	1,611,596	2.59
11	Margot Mary Egan	1,500,000	2.41
12	Grizzly Holdings Pty Limited	999,680	1.61
13	HSBC Custody Nominees (Australia) Limited – A/C 2	938,675	1.51
14	Robert Richter + Anne Lyell Richter <Robert Richter S/F No2 A/C>	925,291	1.49
15	Exit Out Pty Ltd <The Discretionary A/C>	870,456	1.40
16	T S Rai 2 Pty Ltd <Websta Super Fund A/C>	800,000	1.29
17	Buttonwood Nominees Pty Ltd	795,190	1.28
18	Paul Alexander Ehrlich + Lauren Stacey Ehrlich <PAE & LSE Super Fund A/C>	780,000	1.25
19	Benlee Company Pty Ltd <The Benlee A/C>	594,398	0.96
20	UBS Nominees Pty Ltd	576,000	0.93
	Total of Top 20 Holdings	**40,762,713**	**65.56**
	Other Holdings	**21,420,338**	**34.44**
	Total Ordinary Shares	**62,183,051**	**100.00**

Australian Securities Exchange (ASX) Additional Information Cont’d

VOTING RIGHTS

At general meetings of the Company, all fully paid ordinary shares carry one vote per share without restriction. On a show of hands, every member present at a general meeting, or by proxy, shall have one vote and, upon a poll, each share shall have one vote. Option holders have no voting rights until the options are exercised into ordinary shares.

SUBSTANTIAL SHAREHOLDERS

Substantial shareholders in Vectus Biosystems Limited, based on Substantial Shareholder Notices received by the Company, are as follows:

Name	Shares
Kefford Holdings Pty Ltd <The Kefford Family A/C>	**7,122,623**
Regal Partners Funds Management Pty Limited & its associates	**4,009,280**
Mr Maurie Stang	**4,858,952**
Estate of Dr Karen Duggan	**3,278,500**
Mr Bernard Stang	**2,560,500**

Options (ASX:VBSAL to VBSAO) issued under Employee Incentive Plan as at 8 September 2026

Details of Option Holders	Zero Exercise Price Options (various vesting dates)
Vectus x1 contractor	41,816 – expire, if not exercised, on 7 May 2028 (VBSAL)
Vectus x1 employee (CEO / CTO)	621,300 – expire, if not exercised, on 7 May 2030 (VBSAO)

ON-MARKET BUY-BACK

In accordance with ASX Listing Rule 4.10.18, the Company advises that there is no current on-market buy-back.

Corporate Directory

VECTUS BIOSYSTEMS LIMITED

ACN: 117 526 137
ABN: 54 117 526 137

DIRECTORS

Dr Ronald Shnier
Non-Executive Chairman

Mr Maurie Stang
Non-Executive Deputy Chairman

Ms Linda Walters
Non-Executive Director

CHIEF EXECUTIVE OFFICER AND CHIEF TECHNOLOGY OFFICER

Dr Tara Speranza

COMPANY SECRETARY

Mr Robert Waring

REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS

Unit 5, Ground Floor
26-34 Dunning Avenue
Rosebery NSW 2018 Australia

Telephone: **+61 2 8344 1300**
Facsimile: **+61 2 9697 0944**
Email: **info@vectusbiosystems.com.au**
Website: **www.vectusbiosystems.com.au**

SHARE REGISTRY

Computershare Investor Services Pty Limited

Yarra Falls, 452 Johnston Street,
Abbotsford VIC 3067 Australia

GPO Box 2975, Melbourne VIC 3001

Telephone Australia: **1300 850 505**
Telephone international: **+61 3 9415 4000**
Contact: **www.investorcentre.com/contact**
Website: **www.computershare.com**

AUDITOR

UHY Haines Norton

Level 9, 1 York Street,
Sydney NSW 2000 Australia

GPO Box 4137, Sydney NSW 2001

Telephone: **+61 2 9256 6600**
Website: **https://hainesnortonsydney.uhyanz.com.au**

STOCK EXCHANGE LISTING

The Company is listed on the Australian Securities Exchange (ASX Limited). ASX Code: VBS

VECTUS BIOSYSTEMS